View Alert
Originator: DHSC & NHS England and Improvement: Supply disruption alert

Issue date: 29-Nov-2019 15:43:10

Action by recipients:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • NHS Regional Offices
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities
  • Acute Trusts
  • Community Trusts

Information to recipients:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Ofsted recipients
  • Social Care Providers (registered with CAS)
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Director of Public Health
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • DHSC Supply Disruption - Medicines

Action category: Action

Title: Emerade 150 microgram, 300 microgram and 500 microgram adrenaline auto-injector devices

Broadcast content:
All Emerade devices will be unavailable for the foreseeable future.

A class 2 recall of this product was issued via this drug alert on 28 November.

This alert contains a management plan which has been developed in collaboration with NHS England and NHS Improvement, the British Society for Allergy & Clinical Immunology (BSACI), the MHRA and National patient groups.



Additional information: NHS England Regional Offices: please cascade this alert to all primary care contractors.

Alert reference: SDA/2019/010

Action underway deadline: 03-Dec-2019

Action complete deadline: 31-Jan-2020

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency